Adage Capital Partners
TEVA icon

Adage Capital Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Adage Capital Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$80M Buy
+2,360,728
New +$78.6M 0.11% 181
2025
Q3 		– Sell
-534,000
Closed -$8.95M – 976
2025
Q2 		$8.95M Buy
534,000
+50,000
+10% +$807K 0.02% 639
2025
Q1 		$7.44M Sell
484,000
-716,000
-60% -$12.8M 0.01% 640
2024
Q4 		$26.4M Sell
1,200,000
-2,421,899
-67% -$44.1M 0.05% 364
2024
Q3 		$65.3M Buy
3,621,899
+1,518,733
+72% +$26.6M 0.12% 191
2024
Q2 		$34.2M Buy
2,103,166
+1,576,166
+299% +$24.3M 0.06% 302
2024
Q1 		$7.44M Hold
527,000
– – 0.01% 649
2023
Q4 		$5.5M Buy
+527,000
New +$4.92M 0.01% 671
2017
Q4 		– Sell
-250,000
Closed -$4.4M – 748
2017
Q3 		$4.4M Buy
+250,000
New +$5.63M 0.01% 633

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Adage Capital Partners's TEVA Position: Q2 2026 in Review

Adage Capital Partners opened a new position in Teva Pharmaceuticals (TEVA) in Q2 2026: 2,360,728 shares worth $80M. The stake represents 0.11% of the portfolio and ranks #181 among its holdings. This is a return to the name: Adage Capital Partners previously reported a position in TEVA as recently as Q2 2025.

Adage Capital Partners first reported a position in TEVA in Q3 2017 and has held it in 9 quarters since. 675 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Adage Capital Partners held 2,360,728 shares of Teva Pharmaceuticals worth $80M as of Q2 2026.
  • Teva Pharmaceuticals was a new Adage Capital Partners position in Q2 2026.
  • Teva Pharmaceuticals made up 0.11% of Adage Capital Partners's portfolio in Q2 2026, its #181 holding.
  • Adage Capital Partners first reported a position in Teva Pharmaceuticals in Q3 2017 and has held it in 9 quarters since.
  • 675 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.